Assertio Holdings Inc
NASDAQ:ASRT
Assertio Holdings Inc
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Rolvedon Sales Surge: Assertio reported Rolvedon net product sales of $38.6 million in Q3 2025, up sharply from $15 million a year ago due to a two-quarter sales pull-forward.
Strong Profit Growth: Adjusted EBITDA rose to $20.9 million from $4.4 million last year, primarily driven by the Rolvedon pull-forward.
Guidance Narrowed: Full-year 2025 product sales guidance tightened to $110–112 million and adjusted EBITDA to $14–16 million, reflecting greater visibility after the Rolvedon pull-forward.
Temporary Cash Flow Dip: The Rolvedon sales shift will cause a temporary drop in operating cash flow over the next two quarters, with sales of newly labeled Rolvedon expected to resume in Q2 2026.
Sympazan Grows Modestly: Sympazan sales edged up to $2.8 million from $2.6 million, supported by higher volume.
Indocin Declines: Indocin sales fell to $4.8 million from $5.7 million, as expected from rising generic competition.
Gross Margin Dips: Gross margin decreased to 72% from 74% last year due to the higher mix of Rolvedon sales.
